Alphyn Biologics (Alphyn) is a privately held limited liability company.  Alphyn has an experienced, successful international leadership team and exceptional advisory boards that include key thought leaders, researchers, and practitioners in infectious disease, oncology, skin diseases, regulatory approvals, and the life science and consumer industries.

Our Investors, Financing, and Use of Proceeds

Alphyn recently closed its first round of outside financing, raising funds from private investors with medical, life science industry, and legal backgrounds. Alphyn used the proceeds from this first financing for projects needed to complete its successful FDA Pre-IND meeting and advance projects needed to begin its Phase II human clinical trial program for its first product to treat drug resistant skin infections.

The company is readying its second round of financing, which will be used to complete the projects necessary to move Alphyn’s first product, MRSA-1, forward for submission of the FDA Investigational New Drug Application (IND) and the start of Phase II human clinical trial.  MRSA-1 is a topical antibiotic targeted to treat and cure drug-resistant infections, including MRSA drug-resistant infections.

If you are interested in learning more about Alphyn, or for financial or investment inquiries, please contact Neal Koller at +1 888-504-1150 or use the form below:

Yes, please add me to Alphyn’s email list.


Coming Soon


CEO and Chairman of Alphyn Biologics talks with CONNECTpreneur Anchor and Phoenix Fund General Partner

Neal Koller, CEO and Chairman of Alphyn Biologics, talks with Laura Hill, CONNECTpreneur Anchor and Phoenix Fund General Partner in Tysons Corner, Virginia in February, 2020 Alphyn is a life science company developing proprietary drug therapy for treating serious skin diseases. The initial target indication are skin infections caused by deadly drug-resistant MRSA bacteria based…

Read more

BIO International 2019

BIO International 2019 Alphyn was selected to present at BIO International 2019 on June 6, 2019, in Philadelphia, Pennsylvania.  Chairman & CEO Neal Koller presented.

Read more